STOCK TITAN
  1. Home
  2. News
  3. ANNX

Annexon, Inc. - ANNX STOCK NEWS

Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.

Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics aimed at treating complement-mediated neurodegenerative and autoimmune diseases. The company's unique scientific approach targets C1q, the initiating molecule of the classical complement pathway, to halt the inflammatory cascade before it starts, providing significant potential benefits across a range of diseases affecting the body, brain, and eye.

Annexon’s primary product candidates include:

  • ANX005: A monoclonal antibody designed to block C1q, currently in pivotal Phase 3 trials for Guillain-Barré Syndrome (GBS) and showing promising results in reducing muscle strength loss and nerve damage.
  • ANX007: An antigen-binding fragment aimed at treating geographic atrophy (GA) in the eye, demonstrating notable protection against vision loss and retinal damage in Phase 2 trials.
  • ANX1502: An oral small molecule inhibitor targeting autoimmune diseases, expected to generate proof-of-concept data in the second half of 2024.

In recent developments, Annexon announced positive top-line results from their Phase 3 trial of ANX005 in GBS, showing significant improvements in clinical outcomes and muscle strength. This trial marks a major milestone as ANX005 could become the first targeted treatment for GBS in the U.S. The company also showcased ANX007's potential in preserving retinal structures and vision in GA patients, with Phase 3 trials set to commence in 2024.

Financially, Annexon maintains a robust balance sheet with approximately $260 million in cash and equivalents, providing a runway into mid-2026. The company recently completed a public offering to raise additional capital, further strengthening its financial position to advance its clinical programs.

Annexon continues to advance its pipeline rigorously, with multiple upcoming milestones that have the potential to generate substantial value for patients and shareholders alike.

News

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Annexon, Inc. grants inducement awards to two new non-executive employees under Nasdaq Listing Rule 5635(c)(4), offering options to purchase 27,480 shares of common stock at $5.74 per share, vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.36%
Tags
none
-
News

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) will have its president and CEO, Douglas Love, participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. The company is focused on developing novel therapies for complement-mediated neuroinflammatory diseases. The event will be webcast live and available for replay on the Annexon website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
-
News

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Rhea-AI Summary
Annexon, Inc. (ANNX) announces pivotal Phase 3 data for ANX005 in Guillain-Barré Syndrome (GBS) expected in Q2 2024, initiation of Phase 3 ANX007 ARCHER II trial in Geographic Atrophy (GA) in mid-2024, and clinical proof-of-concept data with ANX1502 oral inhibitor of the Classical Pathway in the second half of 2024. The company reported a robust balance sheet with approximately $260 million in cash, cash equivalents, and short-term investments as of December 31, 2023, ensuring runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.52%
Tags
earnings
News

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Annexon, Inc. grants an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan. The employee receives an option to purchase 3,500 shares of Annexon common stock at an exercise price of $6.69 per share, with vesting over 4 years. The award was approved on March 15, 2024, in line with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
News

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Annexon, Inc. (ANNX) will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. The event will focus on Ophthalmology, showcasing the company's complement-based medicines for inflammatory diseases. Douglas Love, the CEO, will represent Annexon in Boston, MA, on March 5, 2024, at 12:10 p.m. ET. Investors can access the live webcast on the company's website and view the replay for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
News

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) will host a virtual R&D Day featuring GBS experts to discuss Guillain-Barré syndrome and their investigational monoclonal antibody ANX005. The event will highlight the current treatment landscape, Annexon's Phase 3 trial, and the commercial approach to the GBS market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
conferences
News

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Annexon, Inc. granted an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan. The employee received an option to purchase 10,800 shares of Annexon common stock at an exercise price of $5.13 per share, vesting over 4 years. The award was approved on February 16, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
none
-
News

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Rhea-AI Summary
Annexon, Inc. (ANX) outlines strategic priorities for 2024, including late-stage clinical milestones for ANX005 in Guillain-Barré Syndrome, ANX007 in Geographic Atrophy, and ANX1502 for autoimmune indications. The company has reported successful $125 million financing, extending its operating runway into the second quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
-
News

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Annexon, Inc. (ANNX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
conferences
News

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Rhea-AI Summary
Annexon, Inc. (NASDAQ: ANNX) announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The total gross proceeds are expected to be approximately $125.0 million. The offering is expected to close on December 26, 2023. Jefferies and TD Cowen are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
offering

FAQ

What is the current stock price of Annexon (ANNX)?

The current stock price of Annexon (ANNX) is $5.23 as of December 20, 2024.

What is the market cap of Annexon (ANNX)?

The market cap of Annexon (ANNX) is approximately 553.2M.

What does Annexon, Inc. specialize in?

Annexon, Inc. specializes in developing novel therapeutics that target complement-mediated neurodegenerative and autoimmune diseases by focusing on the classical complement pathway.

What are Annexon's main product candidates?

Annexon's main product candidates are ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for geographic atrophy (GA) in the eye, and ANX1502 for autoimmune diseases.

What recent achievements has Annexon announced?

Annexon recently announced positive top-line results from its Phase 3 trial of ANX005 in GBS, showcasing significant improvements in clinical outcomes and muscle strength.

What is the financial condition of Annexon?

Annexon maintains a robust balance sheet with approximately $260 million in cash and equivalents, providing a financial runway into mid-2026. They also completed a public offering to raise additional capital.

When are the next key milestones expected for Annexon’s pipeline?

Key milestones are expected in 2024, including the initiation of Phase 3 trials for ANX007 in GA and proof-of-concept data for ANX1502 in autoimmune diseases.

What is the scientific approach of Annexon?

Annexon's scientific approach targets the C1q protein to block the activation of the classical complement pathway, aiming to stop neuroinflammation and its related diseases before they start.

What is the potential impact of ANX007 on GA patients?

ANX007 has shown the potential to preserve retinal structures and vision in patients with geographic atrophy, with Phase 3 trials set to further investigate its efficacy.

How does ANX005 work in treating GBS?

ANX005 works by inhibiting C1q to prevent complement-mediated inflammation, showing significant improvements in muscle strength and nerve damage in GBS patients.

What regulatory designations has ANX005 received?

ANX005 has received Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation from the European Medicines Agency.

Where can I find more information about Annexon?

More information about Annexon can be found on their official website, annexonbio.com.

Stock ANNX logo
Annexon, Inc.

Nasdaq:ANNX

ANNX Rankings

#3015 Ranked by Market Cap
N/A Ranked by Dividends

ANNX Stock Data

553.22M
98.66M
0.5%
106.1%
7.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE